Targeting far higher levels of efficacy in cancer care

We stay very disciplined in our thinking and assumptions about what our significant, expected contributions can be – we re-evaluate and learn constantly (AI). We use AI extensively. We go deep, decide from data (AI), creativity, KOL experiences, spiritual understanding of tumours, apply human judgment science based, add medical and risk return parameters financially – optimise it all – and go for it !

“We work where we work best.”

We own an independent and thorough understanding of our technologies from the University of Vienna managed by ETH Zurich and experienced management, applying AI driven intelligence in immunology to transform key sectors of care moving “closer to cure” (CR) or “cure”

various tissues & cancer types

high medical need & lack of options (EDC)

major cancer types with improvements

Ambition is to reach “cure” (CR/R) for most patients

Higher efficacy in
15 selected cancer types

We only work where our products and technologies work best. We focus inside areas on synergies to reduce costs and risk. We use AI and regulatory advise (FDA, EMA) extensively. It is a “unique, simple and powerful approach” to deliver breakthroughs, our “best “shots and skills” towards “curing cancer

.

We focus and separated
out other major indications

We only work where our products and technologies work best. We also try to “crack the nuts” of the biggest challenges in oncology: pancreatic cancer (PC), non small cell lung cancer (NSCLC) and melanoma in humans (skin cancer, see annimoo.com) under a breakthrough in human cancers’ company, “meedioo.com”. Still exploratory today (2023-25), they represent later, ethical options

As part of EDC companies, we were developed by NEMOO AI Value Builders EDC AG. We continue to benefit from their support and coaching, their structure, networks and governance. We jointly develop our projects, people, teams, indications, new breakthrough products and add simple AI solutions for doctors where needed. We meet for future growth opportunities, creatively, selectively and often

Our team is very solid, science, development, medical, launches and finance

We partner closely with investors, their goals, to create more value together

We follow the medicine, science and focus on solid, risk reduced returns.

Our core team combines a variety of backgrounds and skills, deep practical and operational experience from drug development (Parexel), regulatory affairs (Parexel), pharmaceuticals (Roche, Biogen, AstraZeneca) and biotechnology (Amgen, Biogen), manufacturing (Lonza), scientific & clinical development (NovoNordisk, Roche, Parexel), corporate finance (SP, Merck) and general management (Roche, AZ, Biogen, Cubist, Sobi)

We are positively “driven” with “passion” towards curing cancer

Sara, Christian